Relmada Therapeutics (RLMD) Preferred Shares (2014 - 2015)
Relmada Therapeutics (RLMD) posted quarterly Preferred Shares of $72.0 for Q3 2015, down 97.84% year-over-year from $3337.0 in Q3 2014, and little changed quarter-over-quarter from $72.0 in Q2 2015.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Preferred Shares (2014 - 2015) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Preferred Shares for 2 consecutive years, with $72.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Preferred Shares fell 97.84% year-over-year to $72.0; the TTM figure through Sep 2015 stood at $72.0 (down 97.84% YoY), while the FY2015 annual figure was $72.0, down 89.21% from the prior year.
- Preferred Shares held at $72.0 in Q3 2015 per RLMD's latest filing, from $72.0 in the prior quarter.
- Across five years, Preferred Shares topped out at $3337.0 in Q3 2014 and bottomed at $72.0 in Q2 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | 72.00 |
| Jun 30, 2015 | 72.00 |
| Mar 31, 2015 | 465.00 |
| Dec 31, 2014 | 465.00 |
| Sep 30, 2014 | 3,337.00 |
| Jun 30, 2014 | 667.00 |